3 years ago

Sano Genetics Secures £8.4 Million to Expand Rare Disease Platform

  • Sano Genetics, a UK-based startup developing a platform to connect rare disease patients with personalized medicine providers, has raised £8.4 million in a Series A funding round led by MMC Ventures

  • The funding will be used to expand the platform's reach to over 50 diseases and 6 countries by mid-2023, as well as to grow its teams in the US and Europe

  • Sano Genetics' software allows patients to contribute to precision medicine research at no cost and from home, and the company charges a subscription to its pharma, biotech, and population health clients.

      • ProblemHealthcare

      "It still takes 10 to 15 years for new drugs to reach patients, and many will never make it out of R&D because costs are prohibitive."

      Solution

      "Sano Genetics has developed a platform to connect patients that have rare, chronic diseases with personalised medicine providers. This platform allows patients with rare and chronic conditions, such as Parkinson’s, to contribute to precision medicine research at no cost and from home."

      Covered on